Spain (ES)

Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution ABSORB bioresorbable scaffold versus Xience metallic stent in acute coronary syndromes with treated with percutaneous coronary intervention. A subanalysis of the COMPARE-ABSORB trial (2019) Van Geuns RJ, Smits PC, Chang CC, Wlodarczyk A, Chevalier B, West N, Gori T, et al. Conference contribution Reduction in blood pressure following renal denervation for patients with differing baseline cardiovascular risk (2019) Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Williams B, et al. Conference contribution Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al. Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019) Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al. Conference contribution Delineating the clinical spectrum due to heterozygous TRAF7 missense mutations: A series of 38 cases (2019) Amiel J, Mishra K, Castilla L, Selmer KK, Barak T, Yang S, Blanco-Sanchez B, et al. Conference contribution